Medicine Central™ is a quick-consult mobile and web resource that includes diagnosis, treatment, medications, and follow-up information on over 700 diseases and disorders, providing fast answers—anytime, anywhere. Explore these free sample topics:
-- The first section of this topic is shown below --
- Dengue fever or “breakbone fever” is caused by an arbovirus—dengue virus (DENV)—a Flavivirus, from the Flaviviridae family.
- Single-stranded positive RNA virus with four antigenically distinct serotypes (DENV1, DENV2, DENV3, DENV4)
- Endemic in tropical and subtropical regions of Africa, Asia, and America
Dengue fever is reportable to the CDC.
Estimated 390 million dengue infections per year—96 million have clinical manifestations (1)
- 3.9 billion people, in 128 countries, are at risk for dengue infection.
- The virus is common in tropical and subtropical climates, mostly in urban and residential areas.
- There have been multiple dengue fever outbreaks in the continental United States over the past decade.
Etiology and Pathophysiology
- Dengue is transmitted by the bite from an infected female Aedes mosquito.
- Symptoms appear after a 4- to 7-day incubation period.
- The virus spreads via the reticuloendothelial system.
- The disease has three phases: febrile, critical (plasma leak), and spontaneous recovery (convalescent).
- Dengue hemorrhagic fever (DHF) is a complication of dengue fever thought to be due to antibody-dependent response related to prior exposure to a different serotype with subsequent endothelial dysfunction and vascular instability; can progress to dengue shock syndrome (DSS)
- Residing in or traveling to endemic areas
- Risk factors for the development of DHF include (2):
- Young age; female gender
- High body mass index
- Sequential infection by different DENV serotypes
- CYD-TDV (Dengvaxia) is a prophylactic, tetravalent, live attenuated viral vaccine licensed in several countries in Latin America and Southeast Asia in 2015; vaccination recommended for individuals with history of previous DENV infection or laboratory evidence of prior infection (seropositive individuals), as long as minimalization of risk can be assured (3)[A]
- Avoid mosquito exposure (4)[C].
- Vector control can be achieved through chemical, biologic, and environmental means (e.g., removal of breeding sites—standing water) (5)[C].
- The Aedes mosquito is most active during the day and prefers to bite indoors. Wear protective clothing and use insect repellent to decrease bite exposures.